# Pando Bioscience

> Pando Bioscience is an AI-driven synthetic biology company that engineers better enzymes for the pharmaceutical and diagnostics industries. It pairs a generative-AI design model with an ultra-high-throughput 'one-pot' screening platform that tests roughly 1,000 times more enzyme variants - about 75% faster and 80% cheaper than conventional methods - compressing the design-build-test-learn cycle to about one month. Founded in 2022 by former Ginkgo Bioworks scientists Will Cao and Yang Wang, Pando both improves customers' enzymes and builds its own proprietary enzyme assets, such as the Saiyan-Phi29 polymerase.

- **Founded:** 2022
- **Headquarters:** Watertown, Massachusetts, United States
- **Founders:** Will (Yangxiaolu) Cao (Co-founder & CEO), Yang Wang (Co-founder)
- **Team size:** 5
- **Products:** AI enzyme engineering service, Ultra-high-throughput one-pot screening platform, Generative AI enzyme design model, Saiyan-Phi29
- **Notable:** Reduced the enzyme design-build-test-learn cycle to about one month., Built a screening platform claimed to test ~1,000x more enzyme variants than traditional methods, 75% faster and 80% cheaper., Selected for Y Combinator's Winter 2023 batch.

## Products & services

- **AI enzyme engineering service** — Custom enzyme optimization and discovery for pharma, diagnostic, and biotech clients - improving existing enzymes or finding new ones to cut manufacturing costs and increase productivity.
- **Ultra-high-throughput one-pot screening platform** — A screening system that converts diverse biological signals into abundant, quantifiable data under varied conditions, testing roughly 1,000x more enzyme variants at 75% faster and 80% lower cost than traditional methods.
- **Generative AI enzyme design model** — An AI model that proposes specific mutations to enhance multiple enzyme properties at once, learning continuously from screening data across each design-build-test-learn cycle.
- **Saiyan-Phi29** — A proprietary high-fidelity Phi29 polymerase - an example of Pando's own enzyme assets for molecular biology and sequencing applications.

## Achievements

- Reduced the enzyme design-build-test-learn cycle to about one month.
- Built a screening platform claimed to test ~1,000x more enzyme variants than traditional methods, 75% faster and 80% cheaper.
- Selected for Y Combinator's Winter 2023 batch.
- Developed proprietary enzyme assets including the Saiyan-Phi29 polymerase.
- Founders published first-author papers in Cell and Nature Biotechnology.

## Latest updates

- **2024-04** — Latest recorded seed funding activity.
- **2023-04** — Raised $500K around its Y Combinator W23 participation.
- **2023-02** — Launched publicly via Y Combinator with its AI-plus-screening enzyme platform.

## Links

- Website: https://pando.bio
- LinkedIn: https://www.linkedin.com/company/pando-bioscience
- Twitter/X: https://twitter.com/cao_will

---

Profile page: https://yespress.io/pando-bioscience-yc-w23
Published by YesPress — https://yespress.io
Last updated: 2026-07-30